Stock Track | Summit Therapeutics Stock Plunges 5.02% on Monday Amid Clinical Trial Collaboration News

Stock Track

Feb 24, 2025

Summit Therapeutics Inc. (SMMT) saw its shares plummet by 5.02% in Monday's pre-market trading session. The biopharmaceutical company's stock movement can be attributed to the following key developments:

Summit announced a clinical trial collaboration with Pfizer to evaluate its investigational drug ivonescimab in combination with several of Pfizer's antibody drug conjugates (ADCs) for the treatment of multiple solid tumors. Under the agreement, Summit will provide ivonescimab for the proposed studies, which are expected to begin in mid-2025. Pfizer will be responsible for conducting the operations and associated costs of these trials.

Additionally, Summit reported its financial results for the fourth quarter and full year ended December 31, 2024. The company posted a wider net loss of $221.3 million, or $0.31 per share, for the full year 2024, compared to a net loss of $614.9 million, or $0.99 per share, in the previous year. Research and development expenses increased significantly to $150.8 million in 2024, up from $59.4 million in 2023, reflecting the company's expanded clinical studies and development costs related to ivonescimab.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127859648"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127859648\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127859648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127859648","market":"hk","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Stock Plunges 5.02% on Monday Amid Clinical Trial Collaboration News","media":"Stock Track","content":"<p>Summit Therapeutics Inc. (SMMT) saw its shares plummet by 5.02% in Monday's pre-market trading session. The biopharmaceutical company's stock movement can be attributed to the following key developments:</p>\n\n<p>Summit announced a clinical trial collaboration with Pfizer to evaluate its investigational drug ivonescimab in combination with several of Pfizer's antibody drug conjugates (ADCs) for the treatment of multiple solid tumors. Under the agreement, Summit will provide ivonescimab for the proposed studies, which are expected to begin in mid-2025. Pfizer will be responsible for conducting the operations and associated costs of these trials.</p>\n\n<p>Additionally, Summit reported its financial results for the fourth quarter and full year ended December 31, 2024. The company posted a wider net loss of $221.3 million, or $0.31 per share, for the full year 2024, compared to a net loss of $614.9 million, or $0.99 per share, in the previous year. Research and development expenses increased significantly to $150.8 million in 2024, up from $59.4 million in 2023, reflecting the company's expanded clinical studies and development costs related to ivonescimab.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Stock Plunges 5.02% on Monday Amid Clinical Trial Collaboration News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Stock Plunges 5.02% on Monday Amid Clinical Trial Collaboration News\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-24 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics Inc. (SMMT) saw its shares plummet by 5.02% in Monday's pre-market trading session. The biopharmaceutical company's stock movement can be attributed to the following key developments:</p>\n\n<p>Summit announced a clinical trial collaboration with Pfizer to evaluate its investigational drug ivonescimab in combination with several of Pfizer's antibody drug conjugates (ADCs) for the treatment of multiple solid tumors. Under the agreement, Summit will provide ivonescimab for the proposed studies, which are expected to begin in mid-2025. Pfizer will be responsible for conducting the operations and associated costs of these trials.</p>\n\n<p>Additionally, Summit reported its financial results for the fourth quarter and full year ended December 31, 2024. The company posted a wider net loss of $221.3 million, or $0.31 per share, for the full year 2024, compared to a net loss of $614.9 million, or $0.99 per share, in the previous year. Research and development expenses increased significantly to $150.8 million in 2024, up from $59.4 million in 2023, reflecting the company's expanded clinical studies and development costs related to ivonescimab.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1127859648","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127859648","pubTimestamp":1740407620,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics Inc.  saw its shares plummet by 5.02% in Monday's pre-market trading session. The biopharmaceutical company's stock movement can be attributed to the following key developments:. Summit announced a clinical trial collaboration with Pfizer to evaluate its investigational drug ivonescimab in combination with several of Pfizer's antibody drug conjugates  for the treatment of multiple solid tumors. Under the agreement, Summit will provide ivonescimab for the proposed studies, whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"受临床试验合作消息影响，Summit Therapeutics股价周一暴跌5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics Inc. (SMMT) saw its shares plummet by 5.02% in Monday's pre-market trading session. The biopharmaceutical company's stock movement can be attributed to the following key developments:\nSummit announced a clinical trial collaboration with Pfizer to evaluate its investigational drug ivonescimab in combination with several of Pfizer's antibody drug conjugates (ADCs) for the treatment of multiple solid tumors. Under the agreement, Summit will provide ivonescimab for the proposed studies, which are expected to begin in mid-2025. Pfizer will be responsible for conducting the operations and associated costs of these trials.\nAdditionally, Summit reported its financial results for the fourth quarter and full year ended December 31, 2024. The company posted a wider net loss of $221.3 million, or $0.31 per share, for the full year 2024, compared to a net loss of $614.9 million, or $0.99 per share, in the previous year. Research and development expenses increased significantly to $150.8 million in 2024, up from $59.4 million in 2023, reflecting the company's expanded clinical studies and development costs related to ivonescimab.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}